Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
Does dapagliflozin reduce the combined risk of worsening heart failure or cardiovascular death in patients with heart failure and a mildly reduced or preserved ejection fraction?
Dapagliflozin reduces the composite risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
Absolute Event Rate: 0% vs 0%
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Solomon et al. (Sat,) reported a other. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.